CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial
CERo Therapeutics Holdings, Inc. (CERO)
Company Research
Source: GlobeNewswire
Study will advance into expanded patient populations with myelodysplastic syndrome (MDS) and myelofibrosis (MF) SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTCQB: CERO) (“CERo” or the “Company”) an innovative cellular immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it has dosed the third patient in the second cohort (sixth patient overall) in its Phase 1 CER-1236 clinical trial in hematologic malignancies. The patient had MDS that evolved to acute myeloid leukemia (AML). The trial was recently expanded to include earlier forms of MDS and myelofibrosis (MF). The study continues to progress in accordance with protocol, with patients undergoing monitoring for safety, pharmacokinetics, pharmacodynamics, and clinical activity. With more than seven days of follow-up completed after the most recent infusion, CERo continues to evaluate key end
Show less
Read more
Impact Snapshot
Event Time:
CERO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CERO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CERO alerts
High impacting CERo Therapeutics Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
CERO
News
- CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial [Yahoo! Finance]Yahoo! Finance
- CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 TrialGlobeNewswire
- CERo Therapeutics Provides Shareholder Update [Yahoo! Finance]Yahoo! Finance
- CERo Therapeutics Provides Shareholder UpdateGlobeNewswire
- CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of DirectorsGlobeNewswire
CERO
Sec Filings
- 4/15/26 - Form 424B3
- 4/15/26 - Form 10-K
- 4/14/26 - Form 424B3
- CERO's page on the SEC website